Download CET4_v3.1_Cetuximab_1stmCRCOxaliplatin

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
National Cancer Drugs Fund Application Form –
Cetuximab
for Metastatic Colorectal Cancer
(1st Line in Combination with oxaliplatin-based
chemotherapy)
Author(s)
David Thomson
Owner
Chemotherapy Clinical Reference Group
Version Control
Version Control
Date
Revision summary
Ver3.0
14 Jul 2014
Introduction of version control and addition of section re-SACT
and monitoring
Ver3.1
07 Sep 2015
Update following national CDF panel meeting
Change to current version
Criteria
Changes
5
Now states “Given with oxaliplatin-based combination chemotherapy regimens”
Note
Removal of note limiting use with other oxaliplatin-based regimens, irinotecanbased combinations or upfront single agent fluoropyrimidine
Title
Now states “1st Line in combination with oxaliplatin-based chemotherapy”
National Cancer Drugs Fund – Application Form 07 Sept 2015
Cetuximab for Metastatic Colorectal Cancer
1st Line in Combination with oxaliplatin-based chemotherapy
Page 1
National Cancer Drugs Fund Application Form –
Cetuximab
for Metastatic Colorectal Cancer
(1st Line in Combination with oxaliplatin-based chemotherapy)
Instructions to Consultants: Please fill in each section of the form electronically and save the
document with your own file name. [If you continue typing the boxes will enlarge to contain the text].
Please send electronically to ______________________. Please also send copies to your Trust’s link
accountant / corporate contracting team.
Security of Patient Identifiable Information: The patient will be identified by their NHS number only.
Please do not include any other patient identifiers for confidentiality reasons. All communication must be
sent to the Cancer Drugs Fund Office via secure e mail accounts: that is from an nhs.net account to the
____________ account.
Receipt of Application: The sender of the application will receive an acknowledgement, together with
details of the unique Cancer Drugs Fund reference.
Cancer Drugs Fund Policy: To check the status of a particular therapy please check the Cancer Drugs
Fund Policy at _________________
Applications will be subject to Clinical Audit arrangements.
BY TICKING THESE BOXES AND SUBMITTING THE APPLICATION THE CLINICIAN IS
CONFIRMING THE PATIENT MEETS ALL THE CRITERIA BELOW. IT SHOULD BE NOTED THAT
THE SACT DATASET WILL BE USED TO MONITOR THAT THESE CRITERIA ARE BEING MET.
Approved Treatment Required for Cetuximab for Metastatic Colorectal Cancer – 1st
Line in Combination with oxaliplatin-based chemotherapy
TICK
All 8 conditions must be met
1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed
by a consultant specialist specifically trained and accredited in the use of systemic
anti-cancer therapy
2. Metastatic colorectal cancer
3. 1st line indication
4. Patients with wild-type RAS
5. Given in combination with oxaliplatin-based chemotherapy regimens
6. Cetuximab given as a 2-weekly regimen at a dose of 500mg/m 2
7. a. Not eligible for NICE TA176 approved indications OR
Or
b. Eligible for treatment under TA176 and no progression after receiving the
approved 16 weeks treatment with cetuximab but unsuitable for surgery and
meeting criteria 1-6
8. No previous treatment with Cetuximab or Panitumumab (unless meeting condition
National Cancer Drugs Fund – Application Form 07 Sept 2015
Cetuximab for Metastatic Colorectal Cancer
1st Line in Combination with oxaliplatin-based chemotherapy
Page 2
7b)
Note: No treatment breaks of more than 4 weeks beyond the expected cycle length are
allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent comorbidities)
Note: If excessive toxicity with oxaliplatin, cetuximab can be continued with a
fluoropyrimidine alone until disease progression only.
Consultant Approval (email authority)
Patient Consent Obtained (date of letter – copy to be retained on patient file)
National Cancer Drugs Fund – Application Form 07 Sept 2015
Cetuximab for Metastatic Colorectal Cancer
1st Line in Combination with oxaliplatin-based chemotherapy
Page 3
Proposed Start Date for Therapy (add clinic date)*:
Consultant details*
(including signature or
email confirmation)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
Trust Pharmacist details of the Trust where
the patient will be
treated*
Mandatory - NHS No*:
Mandatory – Patients
date of birth*
Optional – Hospital No.
Clinical Commissioning
Group*
Patient’s GP*
(name, address,
telephone)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
NHS No:
DOB:
Hospital No:
CCG Name:
Name:
Address:
Post Code:
ICD-10 Code (please tick
the relevant box)*
C18 - Malignant neoplasm of colon
C19 - Malignant neoplasm of rectosigmoid junction
C20 - Malignant neoplasm of rectum
HRG Code
Completion of items marked with * is mandatory. Failure to complete these items may
mean that payment is not made.
National Cancer Drugs Fund – Application Form 07 Sept 2015
Cetuximab for Metastatic Colorectal Cancer
1st Line in Combination with oxaliplatin-based chemotherapy
Page 4